EcoDrugPlus

Integrin, Beta 7

Ensembl ID : ENSDARG00000044318
Gene Symbol: ITGB7
2 Enzyme and pathways 5 Cross references
149 Possible Orthologues:

Integrin, Beta 8

Ensembl ID : ENSDARG00000028222
Gene Symbol: ITGB8
4 Enzyme and pathways 5 Cross references
207 Possible Orthologues:

Interleukin-1 Receptor-Associated Kinase 4

Ensembl ID : ENSDARG00000100534
Gene Symbol: IRAK4
12 Enzyme and pathways 5 Cross references
202 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSDARG00000025375
Gene Symbol: IDH1
9 Enzyme and pathways 5 Cross references
234 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSDARG00000003795
Gene Symbol: IDH2
7 Enzyme and pathways 5 Cross references
250 Possible Orthologues:

Kelch-Like Ech-Associated Protein 1b

Ensembl ID : ENSDARG00000074634
Gene Symbol: KEAP1B
9 Enzyme and pathways 5 Cross references
189 Possible Orthologues:

Kinase Insert Domain Receptor (A Type Iii Receptor Tyrosine Kinase)

Ensembl ID : ENSDARG00000017321
Gene Symbol: KDR
8 Enzyme and pathways 5 Cross references
198 Possible Orthologues:

Kinesin Family Member 11

Ensembl ID : ENSDARG00000010948
Gene Symbol: KIF11
6 Enzyme and pathways 5 Cross references
202 Possible Orthologues:

Kinesin Family Member 5b, A

Ensembl ID : ENSDARG00000074131
Gene Symbol: KIF5BA
5 Cross references
274 Possible Orthologues:

Kinesin Family Member 5b, B

Ensembl ID : ENSDARG00000103394
Gene Symbol: KIF5BB
5 Cross references
275 Possible Orthologues:

Lectin, Galactoside Binding Soluble 3a

Ensembl ID : ENSDARG00000077850
Gene Symbol: LGALS3A
3 Enzyme and pathways 5 Cross references
220 Possible Orthologues:

Leukotriene A4 Hydrolase

Ensembl ID : ENSDARG00000006029
Gene Symbol: LTA4H
16 Enzyme and pathways 5 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).